Active Biotech AB Interim report January - June 2012

• Laquinimod - application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M
                     during third quarter 2012   
                   - a Phase III study will be initiated in the US       
• TASQ        - milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target
                     for Phase III study
                   - overall survival data from Phase II study presented
• ANYARA   - Phase III trial continuing according to plan
• 57-57        - a clinical trial in systemic sclerosis/scleroderma in progress
• ISI             - project proceeding as planned
• The organization has been adapted to the company's new direction
• Net sales: SEK 96.6 M (228.8)
• Operating loss: SEK 120.6 M (profit: 70.6)
• Loss after tax: SEK 123.5 M (profit: 77.7)
• Loss per share for the period: SEK 1.79 (earnings: 1.14)
  
   

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95    

Hans Kolam     
CFO     
Tel: +46 (0)46 19 20 44     

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00 


This report is also available at www.activebiotech.com   Fax: +46 (0)46 19 11 00